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In selected patients with colorectal and neuroendocrine liver metastases, the outcome of liver resection
is well established with 5-year survival rates ranging from 25% to 60%. However, the role of liver
resection for non-colorectal non-neuroendocrine (NCRCE) liver metastases has not been fully estab-
lished. Liver metastases in breast cancer are common and a small number of those patients may be
suitable for surgical resection. There have been some case series with low mortality and morbidity and
prolonged survival after liver resection. We performed this review to evaluate the overall and disease
free survival after liver resections for breast metastases. Extensive search of Pubmed, Medline, Cochrane
database was performed and data was analysed. Although mostly case series with smaller number of
patients, outcome has been comparable to colorectal liver metastases in selected group of patients with 5
years survival rate at the range of 20%e60% with main prognostic factors of being the absence of
extrahepatic disease (in exception of isolated pulmonary and bony metastasis) and to achieve an R0
resection.
 2011 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Background
Liver metastases are a common complication of cancer. Surgery
to resect colorectal liver metastases has historically resulted in
a 25%e30% survival at 5 years. However, only 20%e30% of patients
are candidates for surgical resection.1 The oxaliplatin based neo-
adjuvant chemotherapy in combination with biologic agents are
improving the survival by changing the biological behaviour,
therefore, patients with unresectable liver metastases at presen-
tation can achieve secondary resectability rates of 15e40%.2 In
addition, advances in surgical techniques of liver resection have
pushed the boundary of resection. In selected group of patients
with colorectal liver metastases, 5-year survival rates range from
25% to 40%3e5 in published series; with some recent papers
reporting survival rates up to 58%6e60%,7e9 and 10 years survival of
23%10 after liver resection.
In addition, there are data fromneuroendocrine livermetastases
with good survival beneﬁt. Radical surgery including resection of
the primary tumour and resection of liver metastases has been the
main treatment for potentially resectable disease for advanced
neuroendocrine tumours with ﬁve-year and ten-year survival rates
of 61%,11,12 and 35% respectively.12ax: þ44 0 2032993575.
.
Elsevier Ltd on behalf of Surgical AIn recent years, liver metastases from non-colorectal and non-
neuroendocrine (NCRNE) tumours have increasingly been consid-
ered for surgery with evidence of improved survival.13 The
improvements are partly due to advances in surgical techniques,
anaesthetic management and peri-operative patient care, reducing
operative mortality from 0%14e16 to 2%,13,17 in referral centres. Liver
metastases from non-colorectal and non-neuroendocrine origin
especially from breast, kidney, teratoma, melanoma and sarcoma
are increasingly being performed. However, there have been no
randomised studies and no meta-analysis. Despite the increasing
number of hepatectomies for NCRNE liver metastases, the indica-
tions and potential beneﬁts remain unclear as most of the patient
series are small with different primary tumours. This review eval-
uates indications and outcome after liver resections for metastases
from breast cancer.2. Methods
A search of Pubmed, Medline and Cochrane databases was made using the
search terms: hepatectomy (Mesh term), liver resection, hepatic resection, liver
metastases (Mesh term Liver neoplasm), non-colorectal non-neuroendocrine and
breast cancer. All published studies on liver resection for breast liver metastases
were included for consideration.
We excluded studies having less than 9 cases over 6e20 years (see Table 1), non-
English based articles and the articles published by same author over the same study
period from the ﬁnal analysis.ssociates Ltd.
Table 1
Studies on liver resection for Breast cancer liver metastases.
Author, Journal & Year study
period
Patient Numbers & study design Complications (m&m) Survival & outcome
Breast only
32Adam R & Aloia T
et al; Ann Surg. 2006
1984e2004 85 breast ca; Single institute Nil mortality Median and 5-year
overall survivals 46
months and 41%
33Pocard M et al;
Eur J Surg Oncol. 2000
1988e1997 49 breast ca; Single, retrospective data Nil mortality, 12% morbidity Survival 86% at 12 months,
79% at 24 months and
49% at 36 months.
34Thelen A et al;
J Surg Oncol. 2008
1988e2006 39 breast cancer Nil mortality & morbidity 13% overall 1-, 3-, and
5-year survival 77%, 50%,
and 42%, respectively
35Sakamoto Y et al;
World J Surg. 2005
1985e2003 34 breast ca No mortality Overall and disease-free
5-year survival 21% and
16%, respectively
36Raab R et al;
Anticancer Res 18 (1998)
11 yrs 34 breast ca; R0 resection 86%. Mortality 3% Overall 5-year survival
18.4% (median 27 months)
37Vlastos G et al;
Ann Surg Oncol (2004)
1991e2002 31 breast No post-operative mortality The median survival
63 months, Overall 2 and
5-year survival 86% and
61%, respectively
38Yoshimoto M et al;
Breast Cancer Res Treat. 2000
1985e1998 25 breast Nil 2 and 5-year cumulative
survival 71% and 27%,
respectively
23Lubrano J et al;
Surg Today. 2008
1989e2004 16 breast No death Overall 1, 3, and 5-year
survival 94%, 61%, and
33%, respectively. Median
survival 42 months.
39Elias D et al;
Am J Surg. 2003
1986e2000 Total 54 patients, 29 breast had surgery
only, 25 patients had surgery as well as
post-operative Hepatic arterial
infusion chemotherapy (HAIC)
morbidity 12.9%; no mortality 3- and 5-year overall
survival 50% and 34%
24Carlini M et al;
Hepatogastroenterology 2002
Nil available 17 breast Mortality nil and morbidity 2 Actuarial 5-year
survival 46%.
25Caralt M et al;
Ann Surg Oncol. 2008
88e2006 12 breast Nil died, 2 bile leak Median overall survival
35.9 months. Actuarial
1-, 3-, and 5-year survival
100%, 79%, and 33%,
respectively
26Maksan SM et al;
Eur. J. Surg. Oncol. 2000
1984e1998 9 pts breast No death 5-year survival 51%
27Seifert JK et al;
Hepatogastroenterology 1999
1985e1997 15 breast No mortality Overall median survival
following liver resection
was 57 months with 1-,
2- and 3-year survival
rates of 100%, 71.4% and
53.6% respectively
Breast as part of non-colorectal non-neuroendocrine (NCRNE) series
13Adam R et al;
Ann Surg. 2006
1983e2004 Total 1452 pts
Breast 460 (32%), GI 230 (16%),
urologic 206 (14%) & melanoma 148 (10%);
41 French centres; Association of
French Surgeons study,
R0 resection 83%, preop chemo 42%
60-day mortality 2.3% and
a major complication 21.5%
5 years Overall and
disease-free survival
36% and 21% and at
10 years 23% and 15%,
respectively.
Tumour recurrence 67%
of patients
15Weitz et al;
Annals of Surgery 2005
1981e2002 Total 141 patients;
Breast 29; melanoma 17; testicular 17;
gynaecological 19; (ovarian 12); renal 11;
GI 12; Observational study
(longitudinal type)
Post-operative mortality 0%;
46 (33%) post-operative
complications
5 years survival 24%
40Yedibela S et al; Annals
of Surgical oncology 2005
1978e2001 Total 152 patients;
Stomach 31, pancreas 21, breast 24, SB 17,
kidney & GU 27,
melanoma 5, sarcoma 8; Single institutional
retrospective cohort studies;
Morbidity 29%, mortality 9% Overall 2- and 5-year
survival 49% and 26%,
respectively; Median
survival up to 23 months
41Reddy SK et al;
J Am Coll Surg 2007
1995e2005 Total 82 patients; Breast 20, ovarian 11, renal 4,
sarcoma 19, melanoma 18, gastric 1; retrospective
comparative
Mortality 4%, complication 30% Actuarial 5-year overall
and disease-free survival
37% and 16%, respectively.
28O’Rourke TR et al; Annals
of Surgical Oncology 2007
1986 to
2006
Total 102 patients; GU 32 (Renal 16) ovarian 12)
melanoma 15, breast 11, sarcoma 3;
between 2 hospitals
Mortality and morbidity 0.8% and
21.1%, respectively
Median survival 42 months
and Overall Survival at 3
and 5 years 56.1% and
38.5%, respectively.
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Table 1 (continued )
Author, Journal & Year study
period
Patient Numbers & study design Complications (m&m) Survival & outcome
17Elias D, Lasser P et al.
J Am Coll Surg. 1998
1984e1996 Total 147 patients. 35 breast, 27 neuroendocrine,
20 testicular, 13 sarcomas and 11 gastric,
10 melanomas and 7 gallbladder,
6 gynaecological; single centre
Mortality 2%. The crude 5-year
survival 36%
Five-year survival 20%
for 35 breast cancers
42Ercolani G et al;
Ann Surg Oncol. 2005
1990 to 2003 Total 83 cases
gastrointestinal 18, breast 21, genitourinary 15,
leiomyosarcoma 10,
No mortality, 21% morbidity The 3 and 5-year
actuarial survival 49.5%
and 34.3%;
3- and 5-year actuarial
survival 53.9% and 24.6%
from breast cancer
29Earle SA et al;
J Am Coll Surg. 2006
1990e2005 Total 76 cases;
Pancreas 12, stomach 3; sarcoma 19, breast 10,
kidney 10, gynaecological 10, melanoma 4;
Mortality 2.1%, and post-operative
complications 15.8%
Median survival 36 months,
and 5-year survival 34.9%.
30Lendoire J et al;
HPB, 2007
1989 to 2005 Total 106,
renal 21, ovarian
14, sarcoma 23, breast 19, melanoma 6, gastric 3,
other GI 4; 5 centres, Cross sectional study
Perioperative mortality 1.8% Overall survival 1, 3
and 5 yrs is 67%, 34% and
19% respectively. 5-year
survival 53% for breast
origin
31Cordera F et al;
J Gastrointest Surg 2005
1988e1998 Total 64 patients;
GI 12, GU 28, soft tissue 15 (Breast 10),
3 lung; retrospective study at Mayo clinic
Mortality 1.5% Actual 1-, 3-, and 5-year
survivals 81%, 43%, and
30%, respectively
Studies not included: having less than 10 patients of breast ca
19Harrison et al; Surgery 1997 1980e1995 Total 96 patients; sarcoma 27, melanoma 7, breast 7,
testicular 9, adrenal 7, renal 5, ovary 7, gastric 5,
8 unknown;
Cross Sectional study
No post-operative complications,
but no details given on death
Survival at 1, 3 and
5 yrs 80%, 45% and
37% respectively
20Karavias et al;
European Journal of
Surgical Oncology 2002
1994e2000 Total 18 patients;
Breast 4, kidney 6; gastric 4; intestinal
leomyosarcoma 2;
Observational (longitudinal type)
3 cases: pulmonary atelectasis
and bile leakage
Median survival 3.2 years
21Benevento A et al;
J Surg Oncol. 2000
1988e1998 Total 18 patients; breast 4, gastric 5 Nil mortality, 8 complications Overall actuarial
survival 54% at 1 year,
42% at 2 years, and 21%
at 5 years
22Goering JD et al;
Am J Surg. 2002
1991e2001 Total 42 (13 neuroendocrine); 3 renal, 8 ovarian,
sarcoma 10, breast 3, melanoma 2
1 operative mortality (2%) Overall survival rates at
1, 3, and 5 years are 82%,
55%, and 39%, respectively
(median survival, 45 months).
16Laurent C et al;
World J Surg. 2001
1980e1997 Total 39;
gastrointestinal 15, genitourinary
12, breast 2, sarcoma 3
No mortality Survival at 1, 3, and 5 years
81, 40, and 35%, respectively;
14Hemming et al;
Liver transplantation 2000
1978e
1998
Total 37 patients; 7 pts GI,
7 sarcoma, 7 renal, 5 melanoma;
2 pancreas; breast 1; Observational
study (longitudinal type)
No surgical deaths.
No complications mentioned
Survival at 1, 3 and 5 yrs is
85%, 55% and 45%
respectively; average
survival 46 months
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We analysed data from the studies tabulated below. Authors,
number of participants, design of studies, and summary of study
details have been detailed in the Table 1. Many of the studies
published the data on the NCRNE as a group rather than the indi-
vidual tumour category. Therefore, we included the data from
individual tumour group where enough number of patients were
published with meaningful outcomes and analysed those as an
individual tumour group. Subsequently, we analysed the data on
the NCRNE as a group where more than 9 breast cancer patients
included. There were no randomised controlled trials or systematic
reviews. Essentially all were case series or cohort studies based on
single institution over 10e23 years. Results have been summarised
in Table 1.
The ﬁrst series reporting hepatectomy for metastatic breast
cancer patients alone was published in 1991.18 From that date, 13
studies were identiﬁed with breast cancers liver metastases only
and 16 studies with NCRNE patients with breast cancer subset.
Among these, 6 studies had less than 9 patients14,16,19e22; 9 studies
had 9 or more but less than 20 patients23e31 and 14 series referred
20 or more patients.13,15,17,32e42 Although these studies with oftenconfusing numerical illustration of outcome have been simpliﬁed in
Table 1, we have summarised the results of larger series with 20 or
more patients here to emphasise the signiﬁcant ﬁndings.
Adam et al (see Table 1) analysed the data from 1983 to 2004
from 41 French centres on behalf of Association of French surgeons
of 1452 patients who had non-colorectal non-neuroendocrine
(NCRNE) hepatic metastases resection. Among those 32% i.e. 460
patients had the liver resections for metastases from primary breast
cancer. Following surgery, these patients had 5-year and 10 year
survivals of 41% and 22%, respectively, with a median survival of 45
months. Disease free survival and other complications were not
analysed individually in breast tumour rather it was based on all
patients.
Adam R & Aloia T et al published 85 breast patients from single
institution over 20 years period with median and 5-year overall
survival from the date of diagnosis of liver metastases of 46 months
and41%respectivelyand fromthedateofﬁrst hepatic resectionof 32
months and 37% respectively. Eight patients were alive 5 years after
theirﬁrst hepatectomyand4 of these patientswere alive at 10 years.
All patients have had chemotherapy and hormonal treatment.
Elias D et al, Vlastos G et al, Sakamoto Y et al,Pocard M et al;
Yoshimoto M et al, Raab R et al, Thelen A et al reported 30 to 54
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(3yrs), 27%, 18%, 42% respectively.
Reddy et al, Weitz et al, Yedibela S et al, Ercolani G et al analysed
relatively large data with subgroup of patients with breast primary
liver metastases about 20e30 patients and reported 5 year survival
of 24e37% as a group for NCRNE, whereas disease free survival was
16%e23%. However, it was not possible to infer any survival data
reliably from those studies on any particular tumour. These results
were for R0 resection and extrahepatic diseases were not included
for surgery. In addition, most patients had hormonal treatment and
chemotherapy. However, one Japanese study showed survival only
8.5 months for patients who received standard or non-surgical
therapies.43
3.1. Prognostic indicators
Some report suggests that the disease-free interval (meta-
chronocity) is an important prognostic indicator,26 whereas others
report on the contrary.38 The number and size of hepatic metas-
tases are not thought to predict the outcome,36,38,39 There is no
consensus on the effect of lymph node inﬁltration while some ﬁnd
it negatively prognostic26 and others report it not to inﬂuence the
prognosis.39 The stage of the primary disease appears to be irrel-
evant.36,39 although prior local recurrence of the primary tumour
may have adverse prognostic signiﬁcance.36 Even though clear
resection margins were found to be important in one study36;
surprisingly this was not the case in one of the larger series con-
sisting of 54 patients,39 in which the only variable predicting the
survival was found to be the hormone receptor status of the
disease. However, all other authors described complete resection as
the main prognostic factor. In fact, two criteria almost universally
accepted for selecting patients for curative hepatic resection are
ﬁrstly, the absence of extrahepatic disease (in exception of isolated
pulmonary and bony metastasis) and secondly, the ability of the
surgeon to perform an R0 resection with acceptable mortality.44
Even after these two criteria are met, variations in 5-year survival
after hepatic resection can vary widely as shown in the above data.
4. Discussion
Approximately 50% of breast cancer patients will develop
distant metastases,45,46 and liver metastases are present in 15% of
patients newly diagnosed with metastatic breast cancer and is the
only site of distant disease in one third of these patients.47,48 Ulti-
mately, as many as 50% of patients with stage IV disease will
develop liver metastases with associated median survivals ranging
from 3 to 15 months.49e51 Systemic chemotherapy or hormonal
therapy (or both) is usually indicated for these patients. The liver is
the primary site of recurrence in 12e15% of patients, butmetastases
are conﬁned to the liver in approximately 5% of patients.18,52 One
study found that 10% (9 of 90) of patients with hepatic metastases
from breast cancer were suitable for resection.26 Therefore, the
number of patients with liver metastases from breast cancer who
are currently suitable for liver resection is small. Recently with the
progress in effective multimodal therapies, more patients are being
referred for surgical opinion.
Treatment options available for the management of breast liver
metastases are: hormonal therapy, chemo-radiotherapy, radiolog-
ical or surgical radio frequency ablation, curative intent or cytor-
eductive surgery with or without above combinations, Selective
Internal Radiation Therapy (SIRT) and palliative chemotherapy or
simply palliative care. More than 100 papers have been published
in English literature documenting the outcomes in patients of non-
colorectal non-neuroendocrine (NCRNE) liver metastases treated
with hepatic resection. Among those only the relevant papers onbreast liver metastases have been considered in this review. These
studies report mostly single institutional experiences with a wide
variety of primary tumour types distributed with a small number of
patients over a long period of time (see the Table 1). Furthermore,
they were dated back to early days of liver surgery with developing
technical skills, limited operative accessories and earlier versions of
diagnostic modalities. Therefore, the ability to draw strong
conclusions from these studies is limited.
For breast liver metastases 5 years survival after liver resection
has been 16%e61% in various series. Some of these data are broadly
comparable with the quoted outcome ﬁgure to those achieved
following resection of the colorectal liver metastases depending
upon which spectrum of data one would be comparing with.5,53,54
However, there are some important differences in these two
patients’ groups. Firstly, it is likely that the patients with breast liver
metastases are more selected. Secondly, whereas it is nearly
impossible for patients with colorectal liver metastases to achieve
5-year survival without hepatic resection, the speciﬁc survival
beneﬁt of surgical resection for breast liver metastases is difﬁcult to
differentiate from that of hormono-oncological treatment or
probably from the natural history of the disease.
In contrast to the well-deﬁned guidelines for surgery of colo-
rectal liver metastases, surgical decision for breast liver metastases
is mainly based on institution-based experience and often with
limited evidence based on a smaller number of available retro-
spective studies with fewer patients. For this reason, the clinical
beneﬁts of surgical resection of hepatic metastases from breast
primary tumours are not widely acknowledged yet. On the
contrary, non-surgical treatment does not achieve favourable
outcome and survival amounts to only a few months.55
4.1. Role of cytoreductive surgery
cancers cells are known to produce cytokines and peptidogly-
cans which can precipitate immune complexes and compromise
usual immunological defences. There is an argument that reducing
the burden of cancerous cell volume may provide an immunologic
beneﬁt.56,57 In addition, according to the log-kill hypothesis,
chemotherapeutic agents kill a constant fraction of cells, rather
than a speciﬁc number of cells after each dose.58 Therefore, there
has been a proponent of opinion that reducing the initial tumour
volume increases the likelihood of chemotherapy killing the
number of viable tumour cells. Reducing the total tumour volume
to be treated can also reduce the possibility of drug resistance
development, an event that increases with the number of cancer
cells and the treatment duration.
The diverse nature of primary tumour has an inﬂuence on the
inherent characteristics of liver metastases based on tumour
biology, or the metastatic route or the responsiveness to chemo-
therapy. While selecting breast liver metastases for resection, we
need to consider this inherent tumour biology and responsiveness
to chemotherapy. Rapidly growing tumour tends to be more
aggressive and thus have a poorer prognosis. Metachronicity is
thought to be an indicator of less aggressive disease reﬂecting the
nature of tumour biology. The way tumour behaves is very much
related to histology type, as we know that adenocarcinoma is less
aggressive than squamous cell cancer. This may signify that the
squamous call cancer is less favourable in its cell biology.
Secondly, the liver is a common site of metastasis from various
cancers; however, mechanism and the frequency of spread from
various primaries vary widely. Whereas colorectal liver metastasis
can be regarded as loco-regional spread through portal circulation,
other tumours such as breast liver metastasis may only be ﬁrst site
of distant spread denoting already systemic haematogenous distant
micro-metastases elsewhere. Therefore, prognosis irrespective of
HPB MDM 
Chemotherapy & 
review  
ResectableNon resectable  
±PET-CT  
Breast liver metastases 
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In colorectal liver metastases, extrahepatic disease spread is no
longer considered as inoperable as long as chemotherapy works
well and controls the disease. On the other hand, in breast liver
metastasis curative resection may not achieve favourable outcome
if there is extrahepatic disease except solitary lung metastasis or
isolated bone metastasis; unless it is performed for cytoreductive
purpose. Although the cytoreductive surgery has a proven role in
certain cancers and liver metastases, there is no evidence or any
published series on cytoreductive surgery in breast livermetastases
to date. Unlike other NCRNE liver metastases, breast liver metas-
tasis often respond to hormonal treatment and chemotherapy
depending on the chemo-sensitivity and hormonal status. In fact,
because of systemic dissemination and potential micro-metastases,
combined adjuvant and neoadjuvant chemotherapy alone is often
used to destroy occult cancer cells.Response Extrahepatic 
disease  
Liver resection 
(PVE) 
Palliation
Confined to 
liver  
Restage  
No
Response 
Response No
response  
Chemotherapy/ 
immunotherapy 
?palliative liver 
resection/RFA/SIRT 
Flow chart 1. Proposed algorithm for selection and management of patients with non-
colorectal, non-neuroendocrine liver metastases (NCRNELM). [HPB MDM: Hepato-
pancreato-biliary multidisciplinary meeting; PET: Positron Emission Tomography; CT:
computerised Tomography; PVE: Portal Vein Embolisation; RFA: Radio Frequency
Ablation; SIRT: Selective internal radiation therapy].4.2. Guidelines
The question arises whether the liver resection in breast liver
metastasis lead to improved survival. On balance of above studies,
we believe that liver resection in selected patients with liver
metastasis from breast primary improves survival. Therefore, there
is a need for guidelines to determine which group would beneﬁt
from the liver resection and above all, how the patients with liver
metastases from breast primary should be managed.
In reality, there is a temptation on part of oncologist to continue
chemotherapy until the metastatic tumour disappears or the
disease no longer responds to chemotherapy. This tendency should
be abandoned for the reasons; ﬁrstly, the surgeon should see all the
liver metastases before the chemotherapy to be able to resect all
sites of metastasis as well-responsive liver metastasis can be
difﬁcult to locate for surgery and the available radiological tests
become less sensitive59; secondly, chemotherapy puts enormous
strain on the liver parenchyma causing steatosis and damage to
hepatocyte compromising the quality of residual liver after resec-
tion.60 Therefore, oncologists should refer all patients with liver
metastasis to the surgeon before chemotherapy and all cases
should be discussed in multidisciplinary meeting. Moreover, for
patients who do not respond to initial systemic chemotherapy, it is
now possible to say whether hepatectomy would be appropriate.
Currently, indications for liver resection and treatment protocols
for breast liver metastasis differ considerably depending on the
geographic location as well as the surgeon’s expertise. We, there-
fore, propose some guidelines [see Flow chart 1] for the decision
making based on the grade 3 evidences from the published cohort
studies as described above as well as our own institutional
experiences.
1. All hepatic metastases should be referred to tertiary centre
where large volume hepatic resections are performed and have
available expertise for MDM discussion
2. All patients can be candidate for neoadjuvant and adjuvant
chemotherapy and hormonal therapy depending on the
hormonal status
3. In patients with a normal functioning liver, up to 70% of the
liver volume can be removed without risks of post-operative
failure.61
4. Although the evidences are less clear in breast liver metastases,
similar principles of liver resection for colorectal liver metas-
tases apply
a. Unilobar disease should be resected with hepatectomy
b. Solitary metastasis can be ablated with radio frequency or
resected segmentally or non-anatomicallyc. No clear evidence for liver resection in bilobar multiple
metastases, and nor there is evidence for repeat or staged
resection, however, these can be performed in trial scenario
d. Isolated pulmonary and bony metastasis is not
contraindication
5. Incomplete resection (R1, R2) of breast liver metastasis as
cytoreductive surgery is not proven, although some studies
suggested its role as acceptable.62e64
Although the indications for resection of liver metastases (LM)
from neuroendocrine and colorectal cancers are well-deﬁned and
evolving continuously with minimum of 30% non-cirrhotic liver
residual being acceptable, such has not been the case for LM orig-
inating from other primaries such as breast. In the absence of
known prognostic factors, long-term survival beneﬁt following the
hepatectomy can be unpredictable and may be variable among
these patients. Only a randomized trial comparing surgery versus
no surgery in a well-deﬁned population with breast liver metas-
tases will be able to demonstrate whether liver resection is at all
beneﬁcial in terms of survival and quality of life. However, this type
of study will have its own ethical dilemma.
In conclusion, prolonged survival can be obtained after resection
of liver metastases from breast cancer and they seem to be one of
themost favourable subset of NCRNE liver metastases for surgery. It
has been proposed39 that the liver surgery can, therefore, be
considered as an adjuvant treatment to systemic therapy in
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feasibility of complete resection, no extrahepatic disease (except for
bone metastases which are easily controlled by radiotherapy or
isolated pulmonary metastasis) and no disease progression under
chemotherapy are fulﬁlled.
However, in contrast to the treatment of colorectal liver
metastases where surgery has the key role and chemotherapy acts
as an adjuvant treatment, it is likely that the reverse situation will
be true for breast liver metastases. Multidisciplinary discussions
are required to evaluate the extent of the disease, the degree to
which disease has been controlled and the feasibility of a hepatec-
tomy, the availability of expertise and skills before deciding
whether a patient should undergo surgery or not. When applied
surgery may be able to offer a real beneﬁt in long-term survival in
these situations in selected patients.
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